ED
TNDM icon

Exane Derivatives’s Tandem Diabetes Care TNDM Stock Holding History

Exane Derivatives’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-280
Closed -$32.6K – 936
2022
Q1 		$32.6K Buy
+280
New +$32.7K 0.01% 616

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Exane Derivatives's TNDM Position: Q2 2022 in Review

Exane Derivatives sold out of Tandem Diabetes Care (TNDM) in Q2 2022, closing a stake of 280 shares — an estimated $32.6K sold.

Exane Derivatives first reported a position in TNDM in Q1 2022 and held it in 1 quarter. The position peaked at $32.6K in Q1 2022. 330 funds tracked by Wall St. Rank hold TNDM as of Q2 2022.

  • Exane Derivatives reported no remaining Tandem Diabetes Care position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 280 Tandem Diabetes Care shares in Q2 2022, an estimated $32.6K.
  • Exane Derivatives first reported a position in Tandem Diabetes Care in Q1 2022 and held it in 1 quarter.
  • Exane Derivatives's Tandem Diabetes Care position peaked at $32.6K in Q1 2022.
  • 330 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.